Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
- The PROGRESS Project
- ULYSSES Project
- VerSiLiB Project
- PRODIGI Project
- LASERBLOOD Project
- BioCIPN Project
ULYSSES Project

Title: Ultrasensitive Luminescence-based Yeast Sensors for Specific Early Cancer Sensing,
Acronym: ULYSSES
Official website of the project: https://www.eic-ulysses.eu
Project description
ULYSSES is a pioneering project aimed at developing a non-invasive, portable, and user-friendly biosensor for the early detection of breast and prostate cancers through urine analysis. Its core vision is to identify cancer-related volatile organic compounds (VOCs) and develop a biotechnological device for their detection in urine. The innovation lies in mimicking the extraordinary olfactory system of the nematode Caenorhabditis elegans, which can distinguish cancerous from healthy urine with over 90% accuracy. This ability is mediated by a large repertoire of olfactory receptors (ORs) expressed on specialized sensory neurons. ULYSSES replicates this sensing capacity in a synthetic biology framework by introducing selected C. elegans ORs into engineered yeast (Saccharomyces cerevisiae).
These ORs are functionally coupled to a bioluminescence resonance energy transfer (BRET)-based biosensing construct. Upon binding cancer-associated VOCs, conformational changes in the ORs trigger measurable BRET signal shifts, serving as indicators of cancerspecific profiles with nanomolar sensitivity. In parallel, urine VOCs will be analysed via gas chromatography–mass spectrometry (GCMS).
Machine learning will be applied to the spectral data to identify key compounds that differentiate cancer from healthy samples and link them to specific OR activation profiles. Engineered yeast biosensors, each with a distinct OR-BRET construct, will be arrayed on a disposable device. Upon urine exposure, BRET signal changes will be recorded and interpreted via an AI algorithm trained on
activation heatmaps. This enables the identification of cancer-related patterns with high sensitivity and specificity. Feasibility is ensured by the convergence of expertise within a strongly interdisciplinary consortium. ULYSSES lays the foundation for a versatile diagnostic platform with broad applications in health monitoring and personalized medicine, with strong potential for societal and healthcare impact.
List of Partecipants/Partner
- DISRUPTIVE TECHNOLOGICAL ADVANCES IN LIFE SCIENCE Coordinator
- KOBENHAVNS UNIVERSITET
- UNIVERSITY COLLEGE LONDON
Purpose
ULYSSES aims to develop a novel yeast-based diagnostic device for assessing the oncological risk for breast and prostate cancers using urine samples. To achieve these goals, the establishment of a collaborative network of researchers from diverse sectors is essential.
These objectives are concrete and plausible. The Danish partner has already built a GPCR-based yeast cannabinoid biosensor, resulting in a portable device for point-of-use cannabinoid determination10. The project will be carried out in 8 work packages whose deliverables are measurable and verifiable. ULYSSES aims to achieve TRL 4, with the biosensor validated and operational in the laboratory. Finally, the objectives are realistically achievable within the duration of the project as the necessary know-how and all the key technologies are already available at the host laboratories.
Results
- Generate the yeast biosensor strains harbouring nematode ORs
- Integration into portable diagnostic platform
- Development of an AI-based software
Financial Support
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101256857, acronym ULYSSES, Call HORIZON-EIC-2025-PATHFINDEROPEN.
The total grant of the project is 2.991.106,25 euro
The GRANT assigned to IFO-IRE is 200.000,00 euro (codice CUP IFO-IRE: H53C26000700002)
Principal Investigator: Dr. Paola Nisticò, Tumor Immunology and Immunotherapy Unit of IFO-IRE.




